OpenLB
Open Library of Bioscience
Advanced Search
The Australasian journal of dermatology
Mar, 2025;66 (2): 101-104.

Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.

Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki, Charitomeni Vavouli, Marina Papoutsaki, Maria Politou, Alexander Stratigos, Electra Nicolaidou
Author Information
  1. Ioannis-Alexios Koumprentziotis: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece. ORCID
  2. Natalia Rompoti: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  3. Irene Stefanaki: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  4. Charitomeni Vavouli: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  5. Marina Papoutsaki: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  6. Maria Politou: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  7. Alexander Stratigos: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  8. Electra Nicolaidou: 1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
PMID: 39665153 DOI: 10.1111/ajd.14396

Abstract

No abstract text available.

Keywords

Il���17 inhibitors bimekizumab biologics intraclass switch psoriasis

References

  1. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e952-e953 [PMID: 35770467]
  2. Clin Drug Investig. 2018 Mar;38(3):191-199 [PMID: 29249053]
  3. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):568-575 [PMID: 38147467]
  4. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e7-e8 [PMID: 29846974]
  5. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240-1247 [PMID: 31953892]
  6. Dermatol Ther. 2022 Oct;35(10):e15772 [PMID: 36065488]
  7. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):689-697 [PMID: 36562663]
  8. J Am Acad Dermatol. 2021 Jan;84(1):130-138 [PMID: 32730851]
  9. Br J Dermatol. 2023 Feb 22;188(3):330-340 [PMID: 36751950]
  10. Australas J Dermatol. 2025 Mar;66(2):101-104 [PMID: 39665153]
  11. Arch Dermatol Res. 2019 Jul;311(5):421-424 [PMID: 30879102]
Journal Article

Word Cloud

Created with Highcharts 10.0.0inhibitorsSwitchingwithinclassIL-17treatmentplaquepsoriasis:real-worldretrospectivestudyIl���17bimekizumabbiologicsintraclassswitchpsoriasis

Similar Articles

Cited By